

Cheol Whee Park

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5098698/publications.pdf>

Version: 2024-02-01

96
papers

2,685
citations

201674

27
h-index

206112

48
g-index

99
all docs

99
docs citations

99
times ranked

4856
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Treatment of Glucagon-Like Peptide-1 Analog Exendin-4 Ameliorates Diabetic Nephropathy through Improving Metabolic Anomalies in db/db Mice. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 1227-1238.	6.1	195
2	Resveratrol, an Nrf2 activator, ameliorates aging-related progressive renal injury. <i>Aging</i> , 2018, 10, 83-99.	3.1	143
3	The Adiponectin Receptor Agonist AdipoRon Ameliorates Diabetic Nephropathy in a Model of Type 2 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1108-1127.	6.1	140
4	Accelerated Diabetic Nephropathy in Mice Lacking the Peroxisome Proliferator-Activated Receptor α . <i>Diabetes</i> , 2006, 55, 885-893.	0.6	133
5	Adiponectin receptor agonist AdipoRon decreased ceramide, and lipotoxicity, and ameliorated diabetic nephropathy. <i>Metabolism: Clinical and Experimental</i> , 2018, 85, 348-360.	3.4	106
6	Age-Associated Changes in the Vascular Renin-Angiotensin System in Mice. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-14.	4.0	105
7	The protective effect of resveratrol on vascular aging by modulation of the renin-angiotensin system. <i>Atherosclerosis</i> , 2018, 270, 123-131.	0.8	104
8	Fenofibrate Improves Renal Lipotoxicity through Activation of AMPK-PGC-1 α in db/db Mice. <i>PLoS ONE</i> , 2014, 9, e96147.	2.5	87
9	Effects of Resveratrol on the Renin-Angiotensin System in the Aging Kidney. <i>Nutrients</i> , 2018, 10, 1741.	4.1	74
10	Autophagy attenuates tubulointerstitial fibrosis through regulating transforming growth factor- β 2 and NLRP3 inflammasome signaling pathway. <i>Cell Death and Disease</i> , 2019, 10, 78.	6.3	73
11	Increased C-reactive protein following hemodialysis predicts cardiac hypertrophy in chronic hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 2002, 40, 1230-1239.	1.9	65
12	Resveratrol increases AdipoR1 and AdipoR2 expression in type 2 diabetic nephropathy. <i>Journal of Translational Medicine</i> , 2016, 14, 176.	4.4	64
13	Adenosine monophosphate-activated protein kinase in diabetic nephropathy. <i>Kidney Research and Clinical Practice</i> , 2016, 35, 69-77.	2.2	64
14	Mechanisms of Adiponectin Action: Implication of Adiponectin Receptor Agonism in Diabetic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1782.	4.1	63
15	Cinacalcet-mediated activation of the CaMKK β -LKB1-AMPK pathway attenuates diabetic nephropathy in db/db mice by modulation of apoptosis and autophagy. <i>Cell Death and Disease</i> , 2018, 9, 270.	6.3	56
16	Extracellular Superoxide Dismutase Attenuates Renal Oxidative Stress Through the Activation of Adenosine Monophosphate-Activated Protein Kinase in Diabetic Nephropathy. <i>Antioxidants and Redox Signaling</i> , 2018, 28, 1543-1561.	5.4	53
17	Anthocyanin-rich <i>Seoritae</i> extract ameliorates renal lipotoxicity via activation of AMP-activated protein kinase in diabetic mice. <i>Journal of Translational Medicine</i> , 2015, 13, 203.	4.4	48
18	New therapeutic agents in diabetic nephropathy. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 11-25.	1.7	48

#	ARTICLE	IF	CITATIONS
19	Vascular Endothelial Growth Factor Inhibition by dRK6 Causes Endothelial Apoptosis, Fibrosis, and Inflammation in the Heart via the Akt/eNOS Axis in db/db Mice. <i>Diabetes</i> , 2009, 58, 2666-2676.	0.6	44
20	Inhibition of lymphatic proliferation by the selective VEGFR-3 inhibitor SAR131675 ameliorates diabetic nephropathy in db/db mice. <i>Cell Death and Disease</i> , 2019, 10, 219.	6.3	44
21	Calcimimetic restores diabetic peripheral neuropathy by ameliorating apoptosis and improving autophagy. <i>Cell Death and Disease</i> , 2018, 9, 1163.	6.3	42
22	Inhibition of p300/CBP-Associated Factor Attenuates Renal Tubulointerstitial Fibrosis through Modulation of NF- κ B and Nrf2. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1554.	4.1	42
23	Fimasartan, a Novel Angiotensin-Receptor Blocker, Protects against Renal Inflammation and Fibrosis in Mice with Unilateral Ureteral Obstruction: the Possible Role of Nrf2. <i>International Journal of Medical Sciences</i> , 2015, 12, 891-904.	2.5	40
24	Clinical outcome of kidney transplantation from deceased donors with acute kidney injury by Acute Kidney Injury Network criteria. <i>Journal of Critical Care</i> , 2014, 29, 432-437.	2.2	37
25	Catalytic Antioxidants in the Kidney. <i>Antioxidants</i> , 2021, 10, 130.	5.1	33
26	Therapeutic Effects of Fenofibrate on Diabetic Peripheral Neuropathy by Improving Endothelial and Neural Survival in db/db Mice. <i>PLoS ONE</i> , 2014, 9, e83204.	2.5	33
27	PPAR α agonist, fenofibrate, ameliorates age-related renal injury. <i>Experimental Gerontology</i> , 2016, 81, 42-50.	2.8	32
28	Sustained uremic toxin control improves renal and cardiovascular outcomes in patients with advanced renal dysfunction: post-hoc analysis of the Kremezin Study against renal disease progression in Korea. <i>Kidney Research and Clinical Practice</i> , 2017, 36, 68-78.	2.2	32
29	Vascular Endothelial Growth Factor-Receptor 1 Inhibition Aggravates Diabetic Nephropathy through eNOS Signaling Pathway in db/db Mice. <i>PLoS ONE</i> , 2014, 9, e94540.	2.5	28
30	Tenofovir-associated Fanconi syndrome and nephrotic syndrome in a patient with chronic hepatitis B mono-infection. <i>Hepatology</i> , 2015, 62, 1318-1320.	7.3	27
31	Systematic biomarker discovery and coordinative validation for different primary nephrotic syndromes using gas chromatography-mass spectrometry. <i>Journal of Chromatography A</i> , 2016, 1453, 105-115.	3.7	27
32	Decrease of immature B cell and interleukin-10 during early-post-transplant period in renal transplant recipients under tacrolimus based immunosuppression. <i>Transplant Immunology</i> , 2014, 30, 159-167.	1.2	25
33	Clinical Impact of Pre-transplant Antibodies Against Angiotensin II Type I Receptor and Major Histocompatibility Complex Class I-Related Chain A in Kidney Transplant Patients. <i>Annals of Laboratory Medicine</i> , 2018, 38, 450-457.	2.5	25
34	Attenuated Lymphatic Proliferation Ameliorates Diabetic Nephropathy and High-Fat Diet-Induced Renal Lipotoxicity. <i>Scientific Reports</i> , 2019, 9, 1994.	3.3	22
35	Circulating renalase predicts all-cause mortality and renal outcomes in patients with advanced chronic kidney disease. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 858-866.	1.7	20
36	Dâ€™Pinitol alleviates cyclosporine A-induced renal tubulointerstitial fibrosis via activating Sirt1 and Nrf2 antioxidant pathways. <i>International Journal of Molecular Medicine</i> , 2018, 41, 1826-1834.	4.0	19

#	ARTICLE	IF	CITATIONS
37	Adiponectin receptor agonist ameliorates cardiac lipotoxicity via enhancing ceramide metabolism in type 2 diabetic mice. <i>Cell Death and Disease</i> , 2022, 13, 282.	6.3	19
38	Use of Bortezomib as Anti-Humoral Therapy in Kidney Transplantation. <i>Journal of Korean Medical Science</i> , 2014, 29, 648.	2.5	18
39	Acute kidney injury induced by thrombotic microangiopathy in a patient with hemophagocytic lymphohistiocytosis. <i>BMC Nephrology</i> , 2016, 17, 4.	1.8	18
40	Treatment combining aliskiren with paricalcitol is effective against progressive renal tubulointerstitial fibrosis via dual blockade of intrarenal renin. <i>PLoS ONE</i> , 2017, 12, e0181757.	2.5	17
41	Impact of ABO Incompatibility on the Development of Acute Antibody-Mediated Rejection in Kidney Transplant Recipients Presensitized to HLA. <i>PLoS ONE</i> , 2015, 10, e0123638.	2.5	16
42	Low parathyroid hormone level predicts infection-related mortality in incident dialysis patients: a prospective cohort study. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 160-170.	1.7	16
43	Assessment of tubular reabsorption of phosphate as a surrogate marker for phosphate regulation in chronic kidney disease. <i>Clinical and Experimental Nephrology</i> , 2015, 19, 208-215.	1.6	15
44	Inhibition of xanthine oxidoreductase protects against contrast-induced renal tubular injury by activating adenosine monophosphate-activated protein kinase. <i>Free Radical Biology and Medicine</i> , 2019, 145, 209-220.	2.9	15
45	Fabry disease exacerbates renal interstitial fibrosis after unilateral ureteral obstruction via impaired autophagy and enhanced apoptosis. <i>Kidney Research and Clinical Practice</i> , 2021, 40, 208-219.	2.2	14
46	Risk factors in the progression of BK virus-associated nephropathy in renal transplant recipients. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 865-872.	1.7	14
47	Clinical outcome in patients with chronic antibody-mediated rejection treated with and without rituximab and intravenous immunoglobulin combination therapy. <i>Transplant Immunology</i> , 2014, 31, 140-144.	1.2	13
48	The impact of kidney transplantation on 24-hour ambulatory blood pressure in end-stage renal disease patients. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 427-434.	2.3	13
49	Clinical significance of red blood cell distribution width in the prediction of mortality in patients on peritoneal dialysis. <i>Kidney Research and Clinical Practice</i> , 2016, 35, 114-118.	2.2	13
50	Cardiovascular Risk Comparison between Expanded Hemodialysis Using TheraNova and Online Hemodiafiltration (CARTOON): A Multicenter Randomized Controlled Trial. <i>Scientific Reports</i> , 2021, 11, 10807.	3.3	13
51	Aggravation of diabetic nephropathy in BCL-2 interacting cell death suppressor (BIS)-haploinsufficient mice together with impaired induction of superoxide dismutase (SOD) activity. <i>Diabetologia</i> , 2014, 57, 214-223.	6.3	12
52	Clinical Significance of Pre- and Post-Transplant BAFF Levels in Kidney Transplant Recipients. <i>PLoS ONE</i> , 2016, 11, e0162964.	2.5	12
53	Clinical outcomes and effects of treatment in older patients with idiopathic membranous nephropathy. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 1091-1099.	1.7	12
54	De novo glomerulitis associated with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: A single-center experience. <i>Kidney Research and Clinical Practice</i> , 2013, 32, 121-126.	2.2	11

#	ARTICLE	IF	CITATIONS
55	Clinical effects of pre-transplant serum 25-hydroxyvitamin D level on post-transplant immunologic and non-immunologic outcomes in kidney transplant recipients. <i>Transplant Immunology</i> , 2017, 40, 51-56.	1.2	11
56	Paricalcitol Pretreatment Attenuates Renal Ischemia-Reperfusion Injury via Prostaglandin E ₂ Receptor EP4 Pathway. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-17.	4.0	11
57	The Impact of Obesity on the Severity of Clinicopathologic Parameters in Patients with IgA Nephropathy. <i>Journal of Clinical Medicine</i> , 2020, 9, 2824.	2.4	11
58	Serum Anion Gap Predicts All-Cause Mortality in Patients with Advanced Chronic Kidney Disease: A Retrospective Analysis of a Randomized Controlled Study. <i>PLoS ONE</i> , 2016, 11, e0156381.	2.5	11
59	Paricalcitol attenuates lipopolysaccharide-induced inflammation and apoptosis in proximal tubular cells through the prostaglandin E2 receptor EP4. <i>Kidney Research and Clinical Practice</i> , 2017, 36, 145-158.	2.2	11
60	The Effect of Combination Therapy with Rituximab and Intravenous Immunoglobulin on the Progression of Chronic Antibody Mediated Rejection in Renal Transplant Recipients. <i>Journal of Immunology Research</i> , 2014, 2014, 1-7.	2.2	10
61	The protective effect of neutralizing high-mobility group box1 against chronic cyclosporine nephrotoxicity in mice. <i>Transplant Immunology</i> , 2016, 34, 42-49.	1.2	10
62	Usefulness of assisted procedures for arteriovenous fistula maturation without compromising access patency. <i>Hemodialysis International</i> , 2017, 21, 335-342.	0.9	10
63	Higher Serum Levels of Osteoglycin Are Associated with All-Cause Mortality and Cardiovascular and Cerebrovascular Events in Patients with Advanced Chronic Kidney Disease. <i>Tohoku Journal of Experimental Medicine</i> , 2017, 242, 281-290.	1.2	10
64	Intra-individual variability in high density lipoprotein cholesterol and risk of end-stage renal disease: A nationwide population-based study. <i>Atherosclerosis</i> , 2019, 286, 135-141.	0.8	10
65	Comparison of in vivo biocompatibilities between parylene-C and polydimethylsiloxane for implantable microelectronic devices. <i>Bulletin of Materials Science</i> , 2013, 36, 1127-1132.	1.7	9
66	Benefits of a Continuous Ambulatory Peritoneal Dialysis (CAPD) Technique with One Icodextrin-Containing and Two Biocompatible Glucose-Containing Dialysates for Preservation of Residual Renal Function and Biocompatibility in Incident CAPD Patients. <i>Journal of Korean Medical Science</i> , 2014, 29, 1217.	2.5	9
67	Outcome of endovascular salvage of immature hemodialysis arteriovenous fistulas. <i>Journal of Vascular Access</i> , 2019, 20, 397-403.	0.9	8
68	Cilastatin Preconditioning Attenuates Renal Ischemia-Reperfusion Injury via Hypoxia Inducible Factor-1 α Activation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3583.	4.1	8
69	Safety and immunologic benefits of conversion to sirolimus in kidney transplant recipients with long-term exposure to calcineurin inhibitors. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 552-559.	1.7	7
70	Clinical significance of the presence of anti-human leukocyte antigen-donor specific antibody in kidney transplant recipients with allograft dysfunction. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 157-167.	1.7	7
71	T-type calcium channel blocker attenuates unilateral ureteral obstruction-induced renal interstitial fibrosis by activating the Nrf2 antioxidant pathway. <i>American Journal of Translational Research (discontinued)</i> , 2016, 8, 4574-4585.	0.0	7
72	Niacin in patients with chronic kidney disease: Is it effective and safe?. <i>Kidney Research and Clinical Practice</i> , 2013, 32, 1-2.	2.2	6

#	ARTICLE	IF	CITATIONS
73	Clinical significance of the Kidney Donor Profile Index in deceased donors for prediction of post-transplant clinical outcomes: A multicenter cohort study. PLoS ONE, 2018, 13, e0205011.	2.5	6
74	Henoch-Schönlein purpura secondary to infective endocarditis in a patient with pulmonary valve stenosis and a ventricular septal defect. Korean Journal of Internal Medicine, 2015, 30, 406.	1.7	6
75	Immunologic and non-immunologic complications of a third kidney transplantation. Korean Journal of Internal Medicine, 2015, 30, 657-664.	1.7	6
76	Serum 1,25-dihydroxyvitamin D Better Reflects Renal Parameters Than 25-hydroxyvitamin D in Patients with Glomerular Diseases. International Journal of Medical Sciences, 2017, 14, 1080-1087.	2.5	5
77	Clinical Outcome of Rituximab and Intravenous Immunoglobulin Combination Therapy in Kidney Transplant Recipients with Chronic Active Antibody-Mediated Rejection. Annals of Transplantation, 2017, 22, 468-474.	0.9	5
78	Can management of the components of metabolic syndrome modify the course of chronic kidney disease?. Kidney Research and Clinical Practice, 2020, 39, 118-120.	2.2	5
79	Acute kidney injury with extreme hyperuricemia after antithymocyte globulin treatment in a kidney transplant recipient with underlying aplastic anemia: a case report. BMC Nephrology, 2020, 21, 251.	1.8	4
80	Mortality prediction of serum neutrophil gelatinase-associated lipocalin in patients requiring continuous renal replacement therapy. Korean Journal of Internal Medicine, 2021, 36, 392-400.	1.7	4
81	Changing pattern and safety of pretransplant malignancy in kidney transplant recipients. Kidney Research and Clinical Practice, 2019, 38, 509-516.	2.2	4
82	Recurrent Severe Hyponatremia in a Patient with Sjögren's Syndrome. Electrolyte and Blood Pressure, 2020, 18, 19.	1.8	4
83	Exchange over the guidewire from non-tunneled to tunneled hemodialysis catheters can be performed without patency loss. Journal of Vascular Access, 2018, 19, 252-257.	0.9	3
84	Renal Outcome of IgM Nephropathy: A Comparative Prospective Cohort Study. Journal of Clinical Medicine, 2021, 10, 4191.	2.4	2
85	Response to comment on "New therapeutic agents in diabetic nephropathy". Korean Journal of Internal Medicine, 2017, 32, 570-570.	1.7	2
86	P0135EFFECT OF LYSOPHOSPHATIDIC ACID REGULATION ON THE AGING KIDNEY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	1
87	Clinical predictors of recurrent cephalic arch stenosis and impact of the access flow reduction on the patency rate. Journal of Vascular Access, 2022, 23, 718-724.	0.9	1
88	Role of Renal Replacement Therapy During the Peri-Transplant Period of Heart Transplantation. Annals of Transplantation, 2020, 25, e925648.	0.9	1
89	FP202PARICALCITOL PRETREATMENT ATTENUATES APOPTOSIS AND INFLAMMATION IN RENAL ISCHEMIA-REPERFUSION INJURY VIA PROSTAGLANDIN E2 RECEPTOR EP4. Nephrology Dialysis Transplantation, 2015, 30, iii134-iii135.	0.7	0
90	FP299THE PPAR- α AGONIST, FENOFIBRATE, AMELIORATES AGING-RELATED PROGRESSIVE RENAL INJURY. Nephrology Dialysis Transplantation, 2015, 30, iii167-iii167.	0.7	0

#	ARTICLE	IF	CITATIONS
91	Bilateral perirenal extra-adrenal myelolipoma in a haemodialysis patient. Nephrology, 2018, 23, 604-605.	1.6	0
92	The effect of vascular access type on intra-access flow volume during hemodialysis. Journal of Vascular Access, 2019, 20, 746-751.	0.9	0
93	Unilateral ptosis and painful ophthalmoplegia in a patient with kidney transplantation. American Journal of Transplantation, 2020, 20, 2951-2953.	4.7	0
94	P0966PLACENTAL GROWTH FACTOR DEFICIENCY AGGRAVATES DIABETIC NEPHROPATHY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
95	MO631XANTHINE OXIDASE INHIBITOR AMELIORATES HIGH GLUCOSE-INDUCED OXIDATIVE STRESS BY ACTIVATING AMPK VIA THE ACTIVATION OF PURINE SALVAGE PATHWAY IN GLOMERULAR ENDOTHELIAL CELLS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
96	MO629XANTHINE OXIDASE INHIBITOR ATTENUATES RENAL OXIDATIVE STRESS AND ENDOTHELIAL DYSFUNCTION THROUGH THE INHIBITION OF VEGF-NADPH OXIDASES IN DIABETIC NEPHROPATHY. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0